With new transcatheter options for the repair or replacement of tricuspid valves, the role and timing of repair — whether surgical or minimally invasive — is entering a time of transition.

Edwards Lifesciences (NYSE:EW) reported fourth-quarter sales of $1.39 billion, beating the consensus of $1.36 billion. This ...

For some patients with atrial fibrillation (Afib, AF) and valvular heart disease (VHD), direct oral anticoagulants (DOACs) ...

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2024.

THE Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) has become the first health facility in Gauteng to successfully ...

Heart sounds are one tool providers use to assess heart health. Learn about systolic, diastolic, and S1 to S4 heart sounds in ...

Q4 2024 Earnings Call Transcript February 11, 2025 Edwards Lifesciences Corporation beats earnings expectations. Reported EPS ...

pathophysiology and outcomes of mixed aortic valve disease (MAVD), which refers to combined aortic stenosis and aortic regurgitation. To assess the haemodynamic and clinical severity of MAVD using an ...

For Heart Month, Lynne Currie, the Baptist Heart Valve Coordinator, explained what Mitral Valve Regurgitation is, and what ...

Despite guideline recommendations, the use of bioprosthetic heart valves has surpassed mechanical valves, but data from a large surgical database may lead to a reassessment of that practice.

Patients aged between 50 to 70 years with a mechanical heart valve replacement had better long-term survival compared to those with a biological valve, new research has found.